Novel respiratory syncytial virus-like particle vaccine composed of the postfusion and prefusion conformations of the F glycoprotein

Clinical and Vaccine Immunology

Volumn 23, Issue 6, 2016, Pages 451-459

  Cimica, Velasco ^a   Boigard, Hélène ^a   Bhatia, Bipin ^b   Fallon, John T ^c   Alimova, Alexandra ^d   Gottlieb, Paul ^d   Galarza, Jose M ^a  

^a TechnoVax   (United States)

^b MILLIPORE CORPORATION   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUSION GLYCOPROTEIN; GAMMA INTERFERON; GLYCOPROTEIN; INACTIVATED VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; MATRIX PROTEIN; MEMBRANE ANTIGEN; RESPIRATORY SYNCYTIAL VIRUS LIKE PARTICLE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SQUALENE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMULSION; FEMALE; HISTOPATHOLOGY; HUMAN METAPNEUMOVIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PNEUMONIA; POSTFUSION CONFORMATION; PREFUSION CONFORMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONFORMATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; VIRUS LIKE AGENT; VIRUS REPLICATION;

EID: 84973481041     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00720-15     Document Type: Article

References (40)

1. Meng J, Stobart CC, Hotard AL, Moore ML. 2014. An overview of respiratory syncytial virus. PLoS Pathog 10:e1004016. http://dx.doi.org /10.1371/journal.ppat.1004016.
2. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588-598. http://dx.doi.org/10.1056 /NEJMoa0804877.
3. Knudson CJ, Varga SM. 2015. The relationship between respiratory syncytial virus and asthma. Vet Pathol 52:97-106. http://dx.doi.org/10.1177/0300985814520639.
4. Wu P, Hartert TV. 2011. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther 9:731-745. http://dx.doi.org/10.1586/eri.11.92.
5. Johnson KM, Bloom HH, Mufson MA, Chanock RM. 1962. Natural reinfection of adults by respiratory syncytial virus. Possible relation to mild upper respiratory disease. N Engl J Med 267:68-72.
6. Falsey AR, Singh HK, Walsh EE. 2006. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 78: 1493-1497. http://dx.doi.org/10.1002/jmv.20724.
7. Walsh EE, Falsey AR. 2012. Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets 12:98-102. http://dx.doi.org/10.2174/187152612800100116.
8. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, WHO RSV Vaccine Consultation Expert Group. 2016. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization meeting held on 23-24 March 2015. Vaccine 34: 190-197. http://dx.doi.org/10.1016/j.vaccine.2015.05.093.
9. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113-1117. http://dx.doi.org/10.1126/science.1234914.
10. Magro M, Mas V, Chappell K, Vázquez M, Cano O, Luque D, Terrón MC, Melero JA, Palomo C. 2012. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 109:3089-3094. http://dx.doi.org/10.1073/pnas.1115941109.
11. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, Guarino B, Silacci C, Marcandalli J, Marsland BJ, Piralla A, Percivalle E, Sallusto F, Baldanti F, Lanzavecchia A. 2013. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501:439-443. http://dx.doi.org/10.1038/nature12442.
12. Gilman MSA, Moin SM, Mas V, Chen M, Patel NK, Kramer K, Zhu Q, Kabeche SC, Kumar A, Palomo C, Beaumont T, Baxa U, Ulbrandt ND, Melero JA, Graham BS, McLellan JS. 2015. Characterization of a prefusion- specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog 11:e1005035. http: //dx.doi.org/10.1371/journal.ppat.1005035.
13. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788-7796. http: //dx.doi.org/10.1128/JVI.00555-11.
14. Prince GA, Curtis SJ, Yim KC, Porter DD. 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82:2881-2888. http://dx.doi.org/10.1099/0022-1317-82-12-2881.
15. Bliss CI. 1934. The method of probits. Science 79:38-39. http://dx.doi.org /10.1126/science.79.2037.38.
16. Frey A, Di Canzio J, Zurakowski D. 1998. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 221: 35-41. http://dx.doi.org/10.1016/S0022-1759(98)00170-7.
17. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT. 1999. Histopathologic comparison of human coronary in-stent and postballoon angioplasty restenotic tissue. Am J Cardiol 84:462-466. http://dx.doi.org/10.1016/S0002-9149(99)00334-3.
18. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GBE, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang G-Y, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko S-Y, Todd J-P, Rao S, Graham BS, Kwong PD. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592-598. http: //dx.doi.org/10.1126/science.1243283.
19. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. 2013. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A 110:11133-11138. http://dx.doi.org/10.1073/pnas.1309070110.
20. Ghildyal R, Ho A, Jans DA. 2006. Central role of the respiratory syncytial virus matrix protein in infection. FEMS Microbiol Rev 30:692-705. http: //dx.doi.org/10.1111/j.1574-6976.2006.00025.x.
21. McGinnes Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG. 2015. Murine immune responses to virus-like particleassociated pre- and postfusion forms of the respiratory syncytial virus F protein. J Virol 89:6835-6847. http://dx.doi.org/10.1128/JVI.00384-15.
22. Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, Yang L, McLellan JS, Graham BS, Kwong PD, Schaap- Nutt A, Collins PL, Munir S. 2015. Enhanced neutralizing antibody response induced by respiratory syncytial virus pre-fusion F protein expressed by a vaccine candidate. J Virol 89:9499-9510. http://dx.doi.org /10.1128/JVI.01373-15.
23. Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ, Jones JE, Peterson DL, McCarthy MP, Van Nest G, Milich DR. 2015. Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest 125:1637-1647. http://dx.doi.org/10.1172/JCI78450.
24. Arruvito L, Raiden S, Geffner J. 2015. Host response to respiratory syncytial virus infection. Curr Opin Infect Dis 28:259-266. http://dx.doi.org/10.1097/QCO.0000000000000159.
25. Christiaansen AF, Knudson CJ, Weiss KA, Varga SM. 2014. The CD4 T cell response to respiratory syncytial virus infection. Immunol Res 59: 109-117. http://dx.doi.org/10.1007/s12026-014-8540-1.
26. Stoppelenburg AJ, de Roock S, Hennus MP, Bont L, Boes M. 2014. Elevated Th17 response in infants undergoing respiratory viral infection. Am J Pathol 184:1274-1279. http://dx.doi.org/10.1016/j.ajpath.2014.01.033.
27. Durbin JE, Johnson TR, Durbin RK, Mertz SE, Morotti RA, Peebles RS, Graham BS. 2002. The role of IFN in respiratory syncytial virus pathogenesis. J Immunol 168:2944-2952. http://dx.doi.org/10.4049/jimmunol.168.6.2944.
28. Sheeran P, Jafri H, Carubelli C, Saavedra J, Johnson C, Krisher K, Sánchez PJ, Ramilo O. 1999. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J 18:115-122. http://dx.doi.org/10.1097/00006454-199902000-00007.
29. Rutigliano JA, Graham BS. 2004. Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol 173:3408-3417. http://dx.doi.org/10.4049/jimmunol.173.5.3408.
30. Lambert SL, Aslam S, Stillman E, MacPhail M, Nelson C, Ro B, Sweetwood R, Lei YM, Woo JC, Tang RS. 2015. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One 10:e0119509. http://dx.doi.org/10.1371/journal.pone.0119509.
31. Miller AL, Bowlin TL, Lukacs NW. 2004. Respiratory syncytial virusinduced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis 189:1419-1430. http://dx.doi.org/10.1086/382958.
32. McNamara PS, Flanagan BF, Hart CA, Smyth RL. 2005. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis 191:1225-1232. http://dx.doi.org/10.1086 /428855.
33. Henry RL, Hodges IG, Milner AD, Stokes GM. 1983. Respiratory problems 2 years after acute bronchiolitis in infancy. Arch Dis Child 58:713-716. http://dx.doi.org/10.1136/adc.58.9.713.
34. De Swart RL, Kuiken T, Timmerman HH, van Amerongen G, Van Den Hoogen BG, Vos HW, Neijens HJ, Andeweg AC, Osterhaus ADME. 2002. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 76:11561-11569. http://dx.doi.org /10.1128/JVI.76.22.11561-11569.2002.
35. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108: 9619-9624. http://dx.doi.org/10.1073/pnas.1106536108.
36. Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, Fries LF, Smith GE, Glenn GM. 2014. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine 32:6485-6492. http://dx.doi.org/10.1016 /j.vaccine.2014.09.030.
37. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJM, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JPM. 2015. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 6:8143. http://dx.doi.org/10.1038/ncomms9143.
38. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. 1995. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 6:277-296.
39. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. 2013. The history of MF59 adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 12:13-30. http://dx.doi.org/10.1586/erv.12.140.
40. Cullen LM, Blanco JCG, Morrison TG. 2015. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med 13:350. http://dx.doi.org /10.1186/s12967-015-0705-8.